
The Biotech Giant Poised to Transform the Future: Why Vertex Pharmaceuticals is the Stock to Watch
Vertex Pharmaceuticals stands out in biotechnology with robust financial growth, expecting revenues to reach $10.9 billion by 2024. The company maintains financial stability with successful cystic fibrosis (CF) therapies, despite incurring a strategic net loss of $1.45 billion from acquiring Alpine Immune